US EditionAmgen receives EC approval for Uplizna in gMG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
First and only CD19-targeted therapy approved in Europe for adults with anti-AChR+ and anti-MuSK+ gMG: UPLIZNA demonstrates durable disease control when administered twice annually* THOUSAND OAKS, Calif., February 13, 2026 /PRNewswire/ — Amgen (NASDAQ:AMGN) announced today that the European Commission (EC) has approved UPLIZNA® (inebilizumab) as an add-on treatment to standard therapy for adults with generalized myasthenia gravis (gMG) who are p…
Amgen wins European approval to challenge argenx and UCB for autoimmune market - European Biotechnology Magazine
The European Commission has approved Amgen’s Uplizna in generalized myasthenia gravis, moving the big biotech into a market served by argenx, Johnson & Johnson and UCB. The post Amgen wins European approval to challenge argenx and UCB for autoimmune market appeared first on European Biotechnology Magazine.
pharmaceutical-technology.com
Pharmaceutical Business reviewAmgen receives EC approval for Uplizna in gMG
Amgen has secured EC approval for Uplizna as an add-on treatment to standard therapy for adults with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
